

PATENT  
674525-2001AMENDMENT

Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

IN THE CLAIMS

Please amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows (and as shown in the attached Appendix: Marked Version of Amendments to Show Changes):

E1

27. (Amended) A method of treating T-cell mediated disease or infection comprising administering a medicament comprised of a *Notch* ligand to a patient in need thereof.

E2

29. (Amended) The method of treating T-cell mediated disease or infection of any of claims 27 or 28, wherein the *Notch* ligand is selected from Serrate, Delta or fragments, derivatives or analogs thereof.

E3

32. (Amended) A method of modulating expression of a functional *Notch*[-]protein or *Notch* signaling pathways involving a *Notch* ligand.

E4

38. (Amended) The method of treating T-cell mediated disease or infection of any of claims 27 or 28, or 33-37 wherein the *Notch* ligand is Serrate, or Delta.

39. (Amended) The method of treating T-cell mediated disease or infection of any of claims 33-37, wherein the *Notch* ligand is Serrate, or Delta, or fragments, derivatives or analogs thereof.

40. (Amended) The method of claim 32 wherein the *Notch* ligand is Serrate, or Delta, or fragments, derivatives or analogs thereof.

41. (Amended) The method of claim 32 wherein the *Notch* ligand is Serrate, or Delta.

Please cancel claims 30 and 31, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents